BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
Biopharmaceutical company InnoCare Pharma Ltd. (9969.HK; 688428.SH) announcedon Monday that it, along with KeyMed (2162.HK) and their joint venture have signed a licensing deal for one of their products with…
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
FAST NEWS: InnoCare’s loss narrows on higher lymphoma drug sales
The latest: InnoCare Pharma Ltd. (9969.HK) announced on Monday its third quarter revenue dropped 18.3% year-over-year to 160 million yuan ($21.9 million), while its net loss narrowed 72.2% to 109 million yuan.…
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make…
Recent Articles
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
9969.HK
688428.SHG
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK
688428.SHG
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
- Waiting for new industry dawn, SolarSpace turns to IPO for warmth
